Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTR | P02766 | 1/20 | 0.46 |
| ▸ | PTPRC | P08575 | 2/20 | 0.45 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | PIM1 | P11309 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | CES2 | O00748 | 1/20 | 0.42 |
| ▸ | CES1 | P23141 | 1/20 | 0.42 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.41 |
| ▸ | JAK3 | P52333 | 1/20 | 0.41 |
| ▸ | TLK2 | Q86UE8 | 1/20 | 0.41 |
| ▸ | BACE1 | P56817 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2568947 | 1.00 | TTR (0.46) | TTRPTPRCALOX5KMT2APOLB | |
| SCHEMBL21932250 | 1.00 | TTR (0.46) | TTRPTPRCALOX5KMT2APOLB | |
| SCHEMBL15784451 | 0.85 | CHEK1 (0.44) | TTRPTPRCALOX5KMT2APOLB | |
| SCHEMBL18209554 | 0.85 | ALOX5 (0.47) | PTPRCALOX5KMT2APOLBALDH1A1 | |
| SCHEMBL15784058 | 0.82 | TDP1 (0.44) | TTRPTPRCALOX5KMT2APOLB | |
| SCHEMBL13560482 | 0.82 | TDP1 (0.44) | TTRPTPRCALOX5KMT2APOLB | |
| SCHEMBL3772024 | 0.82 | TDP1 (0.44) | TTRPTPRCALOX5KMT2APOLB | |
| SCHEMBL15408460 | 0.82 | TGM2 (0.42) | HTTALDH1A1LMNAMAPTALOX15 | |
| SCHEMBL14464181 | 0.82 | CSNK1G1 (0.48) | KMT2APOLBHTTALDH1A1LMNA | |
| SCHEMBL15408461 | 0.82 | TGM2 (0.42) | HTTALDH1A1LMNAMAPTALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11987558-B1 | ALK5 inhibitors and their uses | SYNTHIS THERAPEUTICS, INC. (US) | 2024-05-21 | — | — | US | disclosed |
| US-20230372297-A1 | MEDICAMENTS FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES | BOEHRINGER INGELHEIM INT (DE) | 2023-11-23 | — | — | US | disclosed |
| US-20230132568-A1 | ANTIBODY-ALK5 INHIBITOR CONJUGATES AND THEIR USES | SYNTHIS THERAPEUTICS, INC. (US) | 2023-05-04 | — | — | US | disclosed |
| US-11583593-B2 | Antibody-ALK5 inhibitor conjugates and their uses | SYNTHIS THERAPEUTICS, INC. (US) | 2023-02-21 | — | — | US | disclosed |
| EP-3986468-A1 | ANTIB0DY-ALK5 INHIBITOR CONJUGATES AND THEIR USES | Synthis Therapeutics, Inc. (US) | 2022-04-27 | — | — | EP | disclosed |
| US-20210299268-A1 | ANTIBODY-ALK5 INHIBITOR CONJUGATES AND THEIR USES | SYNTHIS THERAPEUTICS, INC. (US) | 2021-09-30 | — | — | US | disclosed |
| EP-3820467-A1 | ANTIBODY-ALK5 INHIBITOR CONJUGATES AND THEIR USES | Synthis Therapeutics, Inc. (US) | 2021-05-19 | — | — | EP | disclosed |
| WO-2020256721-A1 | ANTIB0DY-ALK5 INHIBITOR CONJUGATES AND THEIR USES | SYNTHIS, LLC (US) | 2020-12-24 | — | — | WO | disclosed |
| WO-2020256751-A1 | ANTIB0DY-ALK5 INHIBITOR CONJUGATES AND THEIR USES | SYNTHIS, LLC (US) | 2020-12-24 | — | — | WO | disclosed |
| US-20200330435-A1 | MEDICAMENTS FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES | BOEHRINGER INGELHEIM INT (DE) | 2020-10-22 | — | — | US | disclosed |
| US-20200147234-A1 | ANTIBODY-ALK5 INHIBITOR CONJUGATES AND THEIR USES | SYNTHIS, LLC (US) | 2020-05-14 | — | — | US | disclosed |
| EP-3643309-A1 | MEDICAMENTS FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES | Boehringer Ingelheim International GmbH (DE) | 2020-04-29 | — | — | EP | disclosed |
| US-20190038600-A1 | MEDICAMENTS FOR THE TREATMENT OR PREVENTION OF FIBROTIC DEISEASES | BOEHRINGER INGELHEIM INT (DE) | 2019-02-07 | — | — | US | disclosed |
| US-10154990-B2 | Medicaments for the treatment or prevention of fibrotic diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-12-18 | — | — | US | disclosed |
| US-20160136133-A1 | MEDICAMENTS FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES | BOEHRINGER INGELHEIM INT (DE) | 2016-05-19 | — | — | US | disclosed |
| EP-2878297-A1 | Medicaments for the treatment or prevention of fibrotic diseases | Boehringer Ingelheim International GmbH (DE) | 2015-06-03 | — | — | EP | disclosed |
| US-20140296217-A1 | MEDICAMENTS FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-10-02 | — | — | US | disclosed |
| EP-2384751-A1 | Medicaments for the treatment or prevention of fibrotic diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-11-09 | — | — | EP | disclosed |
| US-20100204211-A1 | MEDICAMENTS FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-08-12 | — | — | US | disclosed |
| US-20060142373-A1 | Medicaments for the Treatment or Prevention of Fibrotic Diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204211-A1 | MEDICAMENTS FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES | MMP1, COL1A1, FOXM1 | TTR 585/4885PTPRC 2932/4885ALOX5 572/4885 |
| US-20060142373-A1 | Medicaments for the Treatment or Prevention of Fibrotic Diseases | MMP1, COL1A1, FOXM1 | TTR 585/4885PTPRC 2932/4885ALOX5 572/4885 |
| US-20200330435-A1 | MEDICAMENTS FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES | MMP1, COL1A1, FOXM1 | TTR 585/4885PTPRC 2932/4885ALOX5 572/4885 |
| US-11987558-B1 | ALK5 inhibitors and their uses | ALK, ALKBH3, ALKBH5 | TTR 2482/4885PTPRC 408/4885ALOX5 685/4885 |
| US-20160136133-A1 | MEDICAMENTS FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES | MMP1, COL1A1, FOXM1 | TTR 585/4885PTPRC 2932/4885ALOX5 572/4885 |
| US-20230372297-A1 | MEDICAMENTS FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES | MMP1, COL1A1, SMAD3 | TTR 388/4885PTPRC 2344/4885ALOX5 506/4885 |
| US-10154990-B2 | Medicaments for the treatment or prevention of fibrotic diseases | MMP1, COL1A1, FOXM1 | TTR 585/4885PTPRC 2932/4885ALOX5 572/4885 |
| US-20140296217-A1 | MEDICAMENTS FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES | MMP1, COL1A1, FOXM1 | TTR 585/4885PTPRC 2932/4885ALOX5 572/4885 |
| US-20210299268-A1 | ANTIBODY-ALK5 INHIBITOR CONJUGATES AND THEIR USES | ALK, ALKBH5, ALKBH3 | TTR 1812/4885PTPRC 334/4885ALOX5 521/4885 |
| US-20190038600-A1 | MEDICAMENTS FOR THE TREATMENT OR PREVENTION OF FIBROTIC DEISEASES | MMP1, COL1A1, IDO1 | TTR 1803/4885PTPRC 2625/4885ALOX5 962/4885 |
| US-11583593-B2 | Antibody-ALK5 inhibitor conjugates and their uses | ALK, ALKBH5, ALKBH3 | TTR 1812/4885PTPRC 334/4885ALOX5 521/4885 |
| US-20200147234-A1 | ANTIBODY-ALK5 INHIBITOR CONJUGATES AND THEIR USES | ALK, ALKBH5, ALKBH3 | TTR 1812/4885PTPRC 334/4885ALOX5 521/4885 |
| US-20230132568-A1 | ANTIBODY-ALK5 INHIBITOR CONJUGATES AND THEIR USES | ALK, ALKBH5, ALKBH3 | TTR 1812/4885PTPRC 334/4885ALOX5 521/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.